Business Context and Reporting Period
Exelixis, Inc. is a biopharmaceutical company focused on cancer medicines, including cabozantinib (CABOMETYX and COMETRIQ) and partnered cobimetinib (COTELLIC). The supplied filing is a Form 10-Q for the quarter ended July 1, 2016, presented for convenience as June 30, 2016—not 2015 Q2 as indicated in the request. Comparisons below are to the corresponding 2015 periods.
Financial Results and Liquidity
Amounts are in millions of dollars except per-share data and margins.
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Total revenue | $36.3 | $8.0 | $51.7 | $17.4 |
| Net product revenue | $31.6 | $8.0 | $40.7 | $17.4 |
| Operating loss | $(25.1) | $(31.3) | $(74.3) | $(54.0) |
| Net loss | $(37.0) | $(43.4) | $(98.4) | $(78.5) |
| Net loss per share, diluted | $(0.16) | $(0.22) | $(0.43) | $(0.40) |
| Gross margin | 95% | 91% | 94% | 92% |
- Revenue mix and growth: Q2 product revenue included $17.6 million from CABOMETYX, launched after FDA approval on April 25, and $14.0 million from COMETRIQ. Q2 revenue rose 354%; first-half revenue rose 197%. Growth reflected the CABOMETYX launch and collaboration revenue.
- Costs: Q2 R&D was $23.0 million, down 6%; first-half R&D was $51.9 million, up 11%. Q2 SG&A was $35.8 million, up 180%; first-half SG&A was $70.7 million, up 217%, largely reflecting CABOMETYX commercialization, personnel, marketing, and related costs.
- Cash flow: First-half operating cash flow was $129.0 million, versus $71.9 million used in 2015, primarily because Ipsen paid a $200 million upfront license fee. Investing activities used $143.5 million; financing provided $2.7 million. Cash and cash equivalents declined $11.8 million to $129.8 million.
- Cash and liquidity: Cash and investments totaled $384.0 million at June 30, including $298.2 million available for operations, $81.6 million of required compensating-balance investments, and $4.2 million of long-term restricted investments. Current assets were $353.4 million and current liabilities $192.8 million.
- Debt: Debt carrying value totaled $396.1 million: $287.5 million principal of 2019 convertible notes, $107.7 million principal of Deerfield notes, and an $80.0 million SVB term loan, net of accounting discounts where applicable. The $80 million term loan is due May 2017; Deerfield notes mature July 2018 and 2019 notes mature August 2019. The filing reports $492.5 million of total indebtedness through maturity.
Material Changes and Management Commentary
- The February 2016 Ipsen agreement granted exclusive cabozantinib commercialization rights outside the U.S., Canada, and Japan. The $200 million upfront fee is recognized over the agreement term; $4.8 million was recognized in first-half 2016, with $195.2 million deferred at June 30.
- Management said cash, investments available for operations, and product revenue were expected to fund operations for at least 12 months after filing, while warning capital needs could arise sooner depending on results, spending, and other factors. The company expected annual net losses for the foreseeable future and did not provide numerical revenue or earnings guidance.
- Management anticipated higher R&D and SG&A in the second half of 2016, including medical-affairs, personnel, and marketing costs supporting CABOMETYX. The company expected significant continued cabozantinib development spending.
- Key development updates: CABOSUN met its primary endpoint in first-line advanced RCC; CELESTIAL top-line results in advanced liver cancer were expected in 2017. A positive EU CHMP opinion for cabozantinib in advanced RCC was announced after quarter-end, on July 22, 2016; EC review remained pending.
Risks, Contingencies, and Unusual Items
- Exelixis filed arbitration against Genentech over COTELLIC development, pricing, commercialization, and U.S. cost and revenue allocations. Genentech filed a counterclaim seeking monetary damages and interest. Exelixis warned an adverse result could require significant payments and increase commercialization costs.
- The Ipsen upfront payment substantially boosted reported operating cash flow; it is not equivalent to recurring operating cash generation. CABOMETYX launch-period channel inventory also affected product revenue, and the company noted early launch gross margins may not represent future margins.
- First-half 2015 product revenue included a one-time $2.6 million COMETRIQ adjustment from changing to sell-in recognition; there was no comparable adjustment in 2016. First-half 2016 also included a $5 million Merck milestone and $1.2 million of COTELLIC ex-U.S. royalties.
- Debt service and refinancing are material risks, including a possible Deerfield mandatory prepayment of up to $27.5 million in January 2017 and the $80 million SVB maturity in May 2017. 2019 notes became convertible at holders’ option during Q3 2016 under a price-based condition, subject to terms disclosed in the filing.
- Other principal risks include commercial uptake and reimbursement, competition, clinical-trial and regulatory uncertainty, reliance on partners and contract manufacturers, and continued operating losses. The company reported no material off-balance-sheet arrangements and no material change in contractual obligations outside the ordinary course.
Important Facts for Investors to Verify
- Confirm the intended reporting period: this filing covers Q2 2016, not Q2 2015.
- Assess recurring product demand separately from launch inventory effects, collaboration milestones, and the Ipsen upfront payment.
- Monitor CABOMETYX uptake, payer access, product margins, and the trajectory of commercialization expenses.
- Track the Genentech arbitration, including any resolution, damages, or changes to COTELLIC cost and revenue allocations.
- Review liquidity available after required bank balances and upcoming debt maturities or potential prepayments.
- Follow regulatory and clinical milestones, especially EU approval, CABOSUN regulatory discussions, and CELESTIAL results.